Markers of acute-phase response in the treatment of pulmonary tuberculosis

Martins, Cristiane Nunes; Gama, Antônio Carlos de Castro; Valcarenghi, Daniela; Batschauer, Anna Paula de Borba

doi:10.5935/1676-2444.20140052

Cited by 14 publications

(14 citation statements)

References 17 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The high concentrations observed for these markers in TB patients in comparison to ORD at baseline, reduced (although not always significantly) in the course of TB treatment. Our observations for CRP, IP-10 and VEGF as salivary candidate markers for monitoring of the response to treatment are in agreement with previous investigations [ 11 , 29 , 30 ]. As discussed previously [ 11 ], larger studies are required to validate the potential of these markers as biomarkers for TB treatment response.…”

Section: Discussionsupporting

confidence: 93%

Diagnostic Potential of Novel Salivary Host Biomarkers as Candidates for the Immunological Diagnosis of Tuberculosis Disease and Monitoring of Tuberculosis Treatment Response

et al. 2016

View full text Add to dashboard Cite

BackgroundThere is an urgent need for new tools for the early diagnosis of TB disease and monitoring of the response to treatment, especially in resource-constrained settings. We investigated the usefulness of host markers detected in saliva as candidate biomarkers for the immunological diagnosis of TB disease and monitoring of treatment response.MethodsWe prospectively collected saliva samples from 51 individuals that presented with signs and symptoms suggestive of TB disease at a health centre in Cape Town, South Africa, prior to the establishment of a clinical diagnosis. Patients were later classified as having TB disease or other respiratory disease (ORD), using a combination of clinical, radiological and laboratory findings. We evaluated the concentrations of 69 host markers in saliva samples using a multiplex cytokine platform, and assessed the diagnostic potentials of these markers by receiver operator characteristics (ROC) curve analysis, and general discriminant analysis.ResultsOut of the 51 study participants, 18 (35.4%) were diagnosed with TB disease and 12 (23.5%) were HIV infected. Only two of the 69 host markers that were evaluated (IL-16 and IL-23) diagnosed TB disease individually with area under the ROC curve ≥0.70. A five-marker biosignature comprising of IL-1β, IL-23, ECM-1, HCC1 and fibrinogen diagnosed TB disease with a sensitivity of 88.9% (95% CI,76.7–99.9%) and specificity of 89.7% (95% CI, 60.4–96.6%) after leave-one-out cross validation, regardless of HIV infection status. Eight-marker biosignatures performed with a sensitivity of 100% (95% CI, 83.2–100%) and specificity of 95% (95% CI, 68.1–99.9%) in the absence of HIV infection. Furthermore, the concentrations of 11 of the markers changed during treatment, indicating that they may be useful in monitoring of TB treatment response.ConclusionWe have identified novel salivary biosignatures which may be useful in the diagnosis of TB disease and monitoring of the response to TB treatment. Our findings require further validation in larger studies before these biosignatures could be considered for point-of-care screening test development.

show abstract

Section: Discussionsupporting

confidence: 93%

Diagnostic Potential of Novel Salivary Host Biomarkers as Candidates for the Immunological Diagnosis of Tuberculosis Disease and Monitoring of Tuberculosis Treatment Response

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In addition to being potentially useful as diagnostic candidates for TB disease, 11 of the markers investigated including CRP, SAP, ferritin, IP-10, α-1-antitrypsin changed with treatment, thereby indicating that they may be potential candidates for monitoring of the response to TB treatment. Although our observations for MMP-2 (increasing levels from baseline to month 6) were contrary to the observations of Ugarte-Gil et al (decreasing levels from baseline to month 6 in sputum culture positive individuals after 2 weeks of treatment) [ 43 ], our observations for CRP, SAP, ferritin, IP-10, and α-1-antitrypsin are in agreement with findings from previous studies [ 44 ] [ 45 ]. More studies are required to validate the potential of these biomarkers, and investigate whether any of the markers would be able to distinguish between clinical cure, treatment failure and relapse.…”

Section: Discussionsupporting

confidence: 75%

Identification of novel host biomarkers in plasma as candidates for the immunodiagnosis of tuberculosis disease and monitoring of tuberculosis treatment response

et al. 2016

View full text Add to dashboard Cite

There is an urgent need for new tools for the rapid diagnosis of tuberculosis disease. We evaluated the potentials of 74 host markers as biomarkers for the immunological diagnosis of tuberculosis and monitoring of treatment response. Fifty-five individuals that presented with signs and symptoms requiring investigation for tuberculosis disease were prospectively recruited prior to clinical diagnosis, at a health centre in Cape Town, South Africa. Patients were later classified as having tuberculosis disease or other respiratory diseases (ORD) using a combination of clinical, radiological and laboratory findings. Out of 74 host markers that were evaluated in plasma samples from study participants using a multiplex platform, 18 showed potential as tuberculosis diagnostic candidates with the most promising being NCAM, CRP, SAP, IP-10, ferritin, TPA, I-309, and MIG, which diagnosed tuberculosis disease individually, with area under the ROC curve ≥0.80. Six-marker biosignatures containing NCAM diagnosed tuberculosis disease with a sensitivity of 100% (95%CI, 86.3-100%) and specificity of 89.3% (95%CI, 67.6-97.3%) irrespective of HIV status, and 100% accuracy in the absence of HIV infection. Furthermore, the concentrations of 11 of these proteins changed with treatment, thereby indicating that they may be useful in monitoring of the response to tuberculosis treatment. Our findings have potential to be translated into a point-of-care screening test for tuberculosis, after future validation studies.

show abstract

“…The serum tests of CRP and ESR indicated the existence of a pretreatment inflammatory process that was attenuated by both treatment schemes (see fig 2.b and c). High pretreatment CRP and ESR levels in both groups of patients were directly related to the degrees of inflammation and disease activity [12], presenting high lung involvement. We found significant differences in CRP and ESR levels between pre- and posttreatment in the two groups (Mood median test, p < 0.001), with no differences between Schemes I and II (Mann Whitney, p > 0.05).…”

Section: Discussionmentioning

confidence: 99%

“…Acute-phase reaction serum tests are essential for monitoring TB patients [10, 11]. The inflammatory reaction causes a characteristic increase in blood proteins [12]. Pulmonary infection with M. tuberculosis is also associated with increased neopterin levels [13].…”

Section: Introductionmentioning

confidence: 99%

A lung image reconstruction from computed radiography images as a tool to tuberculosis treatment control

Oliveira

Duarte

Giacomini

et al. 2019

J. Venom. Anim. Toxins incl. Trop. Dis

View full text Add to dashboard Cite

Background: Background: Tuberculosis (TB) is an infectious lung disease with high worldwide incidence that severely compromises the quality of life in affected individuals. Clinical tests are currently employed to monitor pulmonary status and treatment progression. The present study aimed to apply a three-dimensional (3D) reconstruction method based on chest radiography to quantify lung-involvement volume of TB acute-phase patients before and after treatment. In addition, these results were compared with indices from conventional clinical exams to show the coincidence level. Methods: A 3D lung reconstruction method using patient chest radiography was applied to quantify lung-involvement volume using retrospective examinations of 50 patients who were diagnosed with pulmonary TB and treated with two different drugs schemes. Twenty-five patients were treated with Scheme I (rifampicin, isoniazid, and pyrazinamide), whereas twenty-five patients were treated with Scheme II (rifampicin, isoniazid, pyrazinamide, and ethambutol). Acute-phase reaction: Serum exams included C-reactive protein levels, erythrocyte sedimentation rate, and albumin levels. Pulmonary function was tested posttreatment. Results: We found strong agreement between lung involvement and serum indices pre- and posttreatment. Comparison of the functional severity degree with lung involvement based on 3D image quantification for both treatment schemes found a high correlation. Conclusions: The present 3D reconstruction method produced a satisfactory agreement with the acute-phase reaction, most notably a higher significance level with the C-reactive protein. We also found a quite reasonable coincidence between the 3D reconstruction method and the degree of functional lung impairment posttreatment. The performance of the quantification method was satisfactory when comparing the two treatment schemes. Thus, the 3D reconstruction quantification method may be useful tools for monitoring TB treatment. The association with serum indices are not only inexpensive and sensitive but also may be incorporated into the assessment of patients during TB treatment.

show abstract

Markers of acute-phase response in the treatment of pulmonary tuberculosis

Cited by 14 publications

References 17 publications

Diagnostic Potential of Novel Salivary Host Biomarkers as Candidates for the Immunological Diagnosis of Tuberculosis Disease and Monitoring of Tuberculosis Treatment Response

Diagnostic Potential of Novel Salivary Host Biomarkers as Candidates for the Immunological Diagnosis of Tuberculosis Disease and Monitoring of Tuberculosis Treatment Response

Identification of novel host biomarkers in plasma as candidates for the immunodiagnosis of tuberculosis disease and monitoring of tuberculosis treatment response

A lung image reconstruction from computed radiography images as a tool to tuberculosis treatment control

Contact Info

Product

Resources

About